Tags : Extends

Pharma

Janssen Extends its Research and Licensing Agreement with SVI to

Shots: SVI to receive development milestones, royalties and option exercise fee. Janssen to exercise its option and will be responsible for all development of small molecule modulators of microglial function and inflammation for Alzheimer’s disease In Aug’2017, Janssen collaborated with SVI to develop & commercialize small molecule modulators of microglial function and inflammation focusing the […]Read More

Biotech

Cantargia Extends Licensing Agreement with BioWa for its POTELLIGENT Technology

Shots: The extended agreement allows Cantargia to create and use additional CHO cell lines engineered utilizing BioWa’s POTELLIGENT technology and to develop and commercialize CAN04 developed via CHO cell lines In 2015, Cantargia signed an agreement with BioWa’s technology in advancing its CAN04 to P-IIa clinical study for the treatment of non-small cell lung cancer […]Read More